Panacos Pharmaceuticals, Inc. engages in the discovery and development of small-molecule oral drug which is designed to treat human immunodeficiency virus and other major human viral diseases. The company is headquartered in Watertown, Massachusetts and currently employs 41 full-time employees. The firm's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The firm has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Follow-Up Questions
What is Panacos Pharmaceuticals Inc (PANC)'s P/E Ratio?
The P/E ratio of Panacos Pharmaceuticals Inc is 0
Who is the CEO of Panacos Pharmaceuticals Inc?
Dr. Alan Dunton is the President of Panacos Pharmaceuticals Inc, joining the firm since 2007.
What is the price performance of PANC stock?
The current price of PANC is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Panacos Pharmaceuticals Inc?
Panacos Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is Panacos Pharmaceuticals Inc market cap?
Panacos Pharmaceuticals Inc's current market cap is $0
